per-SVR

In 2016, the MOH tasked the BC-CfE with evaluating health outcomes associated with direct acting antivirals (DAAs) and to identify the population at greatest risk for re-infection in order to understand the larger context driving the overall social and economic costs of HCV infection in BC. To this end, the preservation of sustained virologic response (Per-SVR) study was developed. Per-SVR is Prospective clinical cohort of people recently completed DAAs and achieved sustained virologic response (SVR).

STUDIES MENU

Study Outcomes

  1. rate of reinfection
  2. health care utilization patterns
  3. harm reduction engagement
  4. impacts of treatment on health outcomes over time

Activities

  • At each study visit, UDS & blood sample (HIV, HCV) taken
  • A qualitative sub-study to understand health care experiences of participants who have experienced an HCV reinfection was launched September 2021

Funding Organizations

Scroll to Top

During the Canada Post strike, the following measures have been undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office.  (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During this time, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service.

Start typing and press enter to search